Sygnature Discovery, a provider of integrated drug discovery services, and Cyprotex Discovery Ltd., a specialist ADME-Tox/PK preclinical discovery and development CRO, have entered into an extension of their strategic alliance for a further two years. The companies will expand their collaborative sales and marketing initiative to provide a fully-integrated discovery chemistry/ADME-Tox/DMPK service to accelerate their clients’ drug discovery projects into development. Dr Anthony Baxter, chief ex...